Pfizer settles patent litigation regarding Teva's generic Neurontin

05/31/2011 | Bloomberg

Pfizer reached a settlement with Teva Pharmaceutical Industries that lets the latter continue marketing a generic version of epilepsy medicine Neurontin. Pfizer had said generic Neurontin sold by Teva and its unit Ivax, as well as Actavis Group subsidiary Purepac, infringes a key patent that lasts until 2017.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC